Understand the source comparison
Best SS-LUP-332 Dosage Endurance 2026: Research Compound Comparison
This table compares SLU-PP-332 to other compounds under investigation for endurance enhancement, clarifying why dosage precision matters more for REV-ERB agonists than for alternative mechanisms. SLU-PP-332 REV-ERB agonist. Mitochondrial biogenesis, fat oxidat
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table compares SLU-PP-332 to other compounds under investigation for endurance enhancement, clarifying why dosage precision matters more for REV-ERB agonists than for alternative mechanisms.
- SLU-PP-332
- REV-ERB agonist. Mitochondrial biogenesis, fat oxidation
- 15–20mg daily oral
- 40–70% time-to-exhaustion improvement (Scripps 2024)
- 60–70% bioavailability fasted; reduced 40% with high-fat meals
- Highest selectivity for endurance pathways with minimal circadian disruption. Dosage ceiling at 25mg makes precision critical
- GW501516 (Cardarine)
- PPARδ agonist. Oxidative gene expression
- 10–20mg daily oral
- 68% running time increase (Salk Institute data)
- ~80% oral bioavailability; not affected by meal timing
- Broader metabolic effects but associated with oncogenic concerns in long-term rodent studies. Less selective than SLU-PP-332
- AICAR
- AMPK activator. Mimics exercise signaling
- 500mg daily oral (human equivalent dose)
- 44% endurance increase in sedentary models
- Poor oral bioavailability (~15%); requires high doses
- Mimics exercise adaptations but requires significantly higher dosing. Cost-prohibitive for most research contexts
- SR9009 (Stenabolic)
- REV-ERB agonist (earlier generation)
- 20–30mg daily oral
- 50% increase in running capacity (Scripps 2012)
- Extremely poor oral bioavailability (<5%); often administered subcutaneously
- First-generation REV-ERB agonist with proof-of-concept but impractical oral dosing. SLU-PP-332 was designed to address this limitation
- The bottom line: SLU-PP-332 represents the most orally bioavailable and selective REV-ERB agonist currently available for endurance research, which is why the best SS-LUP-332 dosage endurance 2026 protocols emphasize precision rather than dose escalation. Receptor selectivity means effects are concentrated in skeletal muscle mitochondria rather than distributed across multiple tissue types, reducing off-target outcomes while maintaining endurance-specific benefits.